Changes in HPV prevalence in England following introduction of the bivalent vaccine

December 05, 2018

Share article

The national immunisation programme using the bivalent vaccine against human papillomavirus (HPV) was introduced in England in September 2008. The authors collected residual vulva-vaginal swab specimens from 16 to 24-year-old women attending for chlamydia screening between 2010 and 2016 and tested them for HPV DNA. They completed testing for 15,459 specimens. The authors found that the prevalence of HPV16/18 decreased between 2010/2011 and 2016 from 8.2% to 1.6% in 16-18 year olds, and from 14.0% to 1.6% in 19-21 year olds. Declines were also seen for HPV31/33/45 (6.5% to 0.6% for 16-18 year olds, and 8.6% to 2.6% for 19-21 year olds). This translates to a vaccine effectiveness for HPV16/18 of 82.0% (95%CI 60.6-91.8%) and for HPV31/33/45 of 48.7% (95%CI 20.8-66.8%). Therefore, 8 years after the introduction of the national HPV vaccination programme, there have been significant declines in HPV16/18 and HPV31/33/45.

Read more here

Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, et al. ISSN: J Infect Dis; 218(6): 911-921


Added: December 05, 2018